Brief: Lytix Biopharma Granted Up To NOK 14.3 Mln Of Public Non-Dilutive Funding

Lytix Biopharma AS

17/10/2023 07:06

Oct 17 (Reuters) - Lytix Biopharma AS  LYTIX.OL :
    * GRANTED UP TO NOK14.3M (US$1.3M) OF PUBLIC NON-DILUTIVE FUNDING FROM 'SKATTEFUNN'
    * APPROVAL GIVES LYTIX RIGHT TO CLAIM TAX DEDUCTIONS FOR RELEVANT AND DOCUMENTABLE COSTS
RELATED
TO RESEARCH AND DEVELOPMENT ACTIVITIES IN APPROVED PROJECT FOR PERIOD 2023 TO 2025
    * MAIN OBJECTIVE OF PROJECT IS TO ASSESS SAFETY AND EFFICACY OF LTX-315 IN PATIENTS WITH
ADVANCED
MELANOMA THAT ARE REFRACTORY TO TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS

Source text for Eikon:  ID:nObiphC4Pa 
Further company coverage:  LYTIX.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))